Abstract Identification of prognostic gene expression signatures may enable improved decisions about management of breast cancer. To identify a prognostic signature for breast cancer, we performed DNA methylation profiling and identified methylation markers that were associated with expression of ER, PR, HER2, CK5/6, and EGFR proteins. Methylation markers that were correlated with corresponding mRNA expression levels were identified using 208 invasive tumors from a population-based casecontrol study conducted in Poland. Using this approach, we defined the methylation expression index (MEI) signature that was based on a weighted sum of mRNA levels of 57 genes. Classification of cases as low or high MEI scores was related to survival using Cox regression models. In the Polish study, women with ER-positive low MEI cancers had reduced survival at a median of 5.20 years of followup, HR = 2.85 95 % CI = 1.25-6.47. Low MEI was also related to decreased survival in four independent datasets totaling over 2500 ER-positive breast cancers. These results suggest that integrated analysis of tumor expression markers, DNA methylation, and mRNA data may be an important approach for identifying breast cancer prognostic signatures. Prospective assessment of MEI along with other prognostic signatures should be evaluated in future studies.
Introduction
DNA methylation of CpG dinucleotides within promoter regions of tumor suppressor genes is an early, stable, heritable event that may be associated with loss of mRNA and protein expression and contribute to breast carcinogenesis [1] . Accordingly, analysis of DNA methylation profiling in conjunction with expression of mRNA and protein may identify genes associated with the biology and clinical behavior of breast cancers and aid in clinical management [2] [3] [4] .
Several recent studies employing candidate gene approaches [5, 6] or profiling strategies [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] have identified DNA methylation markers that are associated with breast cancer characteristics or clinical outcomes. These studies demonstrate that DNA methylation is more frequent in estrogen receptor (ER)-positive compared with ER-negative tumors, suggesting that DNA methylation may play a more important role in shaping the biology and behavior of ER-positive cancers [7, 9, 11] . To date, most efforts to identify prognostic signatures for breast cancer have relied on mRNA profiling, but recent studies suggest that integrated analyses using multiple molecular platforms may be promising [7, [19] [20] [21] .
Although many immunohistochemical (IHC) signatures have been described to classify molecular subtypes of breast cancer, the five IHC markers that we used have shown associations with important etiologic and survival differences for breast cancer [2, 22, 23] . We reasoned that evaluation of methylation profiles using these five-key IHC markers could provide new insights on epigenetic markers related to these important pathologic types.
Materials and methods

Study population
Subjects were selected from a population-based breast cancer case-control study, the Polish Breast Cancer Study (PBCS) [24] . The PBCS included 2386 cases and 2502 age and study site matched controls, between ages 20 and 74 years who resided in Warsaw or Łódź, Poland from 2000 to 2003. Breast cancer pathology was reviewed centrally to provide standardized classification. We selected 227 PBCS cases with snap frozen and formalin-fixed paraffin-embedded tumor tissues obtained prior to treatment. Primary treatment (chemotherapy, radiation therapy, and hormone therapy) and vital status for up to 10 years after diagnosis (mean = 7.8 years, SD = 2.1) were collected through review of medical records and national databases in Poland.
Assessment of protein markers in TMAs
To develop a prognostic signature for breast cancer based on mRNA expression, we performed a cross-platform analysis using a multi-step strategy. Specifically, DNA methylation profiling data were first filtered based on significant relationships with protein expression of ER, progesterone receptor (PR), human epidermal Growth factor receptor 2 (HER2), cytokeratin 5/6 (CK5/6), and epidermal Growth factor receptor 1 (EGFR) by immunohistochemical (IHC) analysis using data from the PBCS, a populationbased case-control study.
Fixed tissues were prepared as tissue microarrays (TMAs) and evaluated for expression of ER, PR, HER2, EGFR, or CK 5/6 using automated quantitative analysis (AQUA) as previously described elsewhere [22, 25] . Results of AQUA were highly correlated with results of IHC performed on TMAs and assessed visually and staining of whole sections performed for clinical management [25] . AQUA or IHC data were used to define tumors that were positive for each individual protein marker: ER, PR, HER2, EGFR, and CK 5/6 and the scores for each individual marker were combined to approximate correspondence to the intrinsic molecular subtypes, including luminal (ER or PR positive), HER2 overexpression, and basal (negative for ER, PR, and HER 2 with expression of CK 5/6 or EGFR) as previously described [22, 25] .
DNA isolation and methylation analysis of breast cancer tissues DNA and RNA were isolated by standard protocols simultaneously from 30 mg tissue samples. For DNA, 30 mg of frozen tissue was shaved into 400 ll digestion buffer (0.1 M NaCl, 0.01 M Tris, pH 8.0, 0.025 M EDTA, pH 8.0, and 0.5 % SDS) containing 0.1 mg/ml proteinase K. Samples were incubated overnight at 50°C with gentle rocking and purified using phenol:chloroform:isoamyl alcohol (25:24:1) and PhaseLock Gel (heavy) tubes for DNA extraction. DNA quality and quantity was assessed using agarose gel electrophoresis and PicoGreen dsDNA Quantitation Kit (Molecular Probes, Eugene, OR). Upon bisulfite conversion, DNA methylation status of 27,578 CpG probes was assayed using the Illumina Methylation27 bead-array (Illumina, San Diego CA) using the manufacturer's protocol. Data were extracted from the scanned arrays using Bead Studio. Of the 227 cases, selected 226 had methylation data.
RNA isolation, labeling, and microarray hybridization Frozen tumor samples were stored in liquid nitrogen (-196°C) prior to nucleic acid extraction. RNA was isolated using 350 microliters TRIzol reagent (Invitrogen, Carlsbad, CA) and purified on Qiagen RNAeasy Mini columns per manufacturer protocols. RNA quantity and integrity were assessed using Nanodrop Spectrophotometry (Thermo Scientific, Waltham, MA) and 6000 Nano LabCip Kit on Agilent 2100 BioAnalyzer (Agilent, Santa Clara, CA), respectively. Two-hundred fifty nanograms of input RNA was amplified and labeled using the Illumina TotalPrep RNA Amplification kit (Applied Biosystems/Ambion, Austin, TX). The biotin-labeled cRNAs were quantitated using RiboGreen RNA Quantitation reagent (Molecular Probes, Eugene, OR) and 750 ng was hybridized to Illumina HumanRef-8 v2 Expression BeadChip microarrays (Illumina, San Diego, CA). BeadChips were scanned in an Illumina scanner. Data were deposited with NCBI under GSEXXXXX. Of the 227 cases selected, 208 had usable mRNA expression data.
Data analysis
The representativeness of cases with regard to tumor characteristics or risk factors included in the analysis was compared with the entire set of cases of the original PBCS population using Chi squared or Fisher's exact tests.
Methylation data were processed in the R statistical environment. Analysis of mRNA expression data was processed using the lumi package in Bioconductor (R). These methylation markers were correlated with mRNA profiling data to define a methylation expression index (MEI) composed of 57 genes whose expression was correlated (typically negatively) with DNA methylation.
To develop a prognostic signature, we classified tumors as negative or positive for five IHC markers, ER, PR, HER2, EGFR, and CK5/6, as previously described [22] . Using the methylation data from the Illumina Infinium Human Methylation27 BeadChip, we selected markers related to IHC protein expression, using a Bonferroni adjustment threshold of P \ 1.8e-06. Through this selection process we identified 2227 methylation markers in 1162 genes, which also had corresponding mRNA expression data ( Fig. 1) . In a separate analysis, to identify mRNA markers that had substantial variation, we selected the 3 % most variable mRNA expression probes from the Illumina HumanRef-8 v2 Expression BeadChip, which identified 563 probes corresponding to 541 genes. We selected the 3 % most variable genes based on gene expression and intersected them with the 1162 genes. The intersection resulted in 65 genes. We further selected 57 genes that had spearman correlation absolute values of 0.1 or greater.
We then determined the overlap between the 1162 methlylation marker genes associated with IHC marker Fig. 1 Analysis strategy to define the 57 gene methylation expression index (MEI), using data from 27,578 methylation markers and 22,184 mRNA expression markers from the Polish breast cancer study expression, and the 541 genes with variable mRNA expression data, which identified 65 genes. Because we were interested in methylation markers that could influence mRNA expression, we determined the Spearman correlations coefficients between methylation and mRNA expression among the 65 genes. We further restricted the gene list to those with an absolute Spearman correlation rho equal or greater than 0.1 (for genes with multiple probes we calculated the average), which resulted in 57 genes with corresponding mRNA expression data available in the Polish study (Table 1) . MEI scores were related to demographic, prognostic, and treatment variables using Chi squared or Fisher's exact tests. We assessed the relationship between MEI and overall survival among 208 women with breast cancer who had available mRNA expression data. The Kaplan-Meier (KM) method stratified by ER status was used to generate survival curves for categories of the MEI [26] . Hazard ratios (HR) and 95 % confidence intervals (CI) associated with methylation status adjusted for age (in 5 year categories), tumor size (B2 cm vs. [2 cm), grade (well/moderately differentiated vs poorly differentiated), and node status (positive vs negative) were estimated using Coxproportional hazard models [27] . We checked for violations of the proportional hazards assumption for methylation variables and covariates using Schoenfeld residuals. Interaction with MEI and ER was assessed using an interaction term in Cox models. Analyses were performed using Stata/SE v11.2 for Windows (College Station, TX) and the R statistical environment.
Replication datasets
To validate associations between MEI and breast cancer survival, we analyzed mRNA expression data from four independent datasets. The first consisted of a combined dataset of cDNA microarrays from 337 breast cancer patients (88 ER-negative and 249 ER-positive) age in the range of 26-62 from the Netherlands Kanker Instituut (NKI) [4, 28] . A second dataset included expression data from GEO GSE6532 Affymetrix Human Genome U133A microarray assays from 414 breast cancer patients age in the range of 24-88 available at the National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov/ geo/ [29] . In this dataset, 277 patients, including five with ER-negative cancers, were treated with tamoxifen, while the remaining 137 patients, including 86 of which were ER-positive were untreated. The third dataset is the TCGA breast cancer dataset [19] and used data on 532 patients (407 of which were ER-positive) age in the range of 26-90 with both gene expression and survival data. The fourth dataset was from METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) with expression data on 1992 patients of which 1508 were ER-positive (referred to as BT2000) [20] . Gene expression data were weighted by the correlation of methylation with expression determined in the PBCS dataset. The correlations provided a way to combine gene expression so that a gene with less correlation had less contribution to the MEI.
Results
Development of methylation expression index (MEI)
Cases included in this study ranged in age from 28 to75 years, with a median age of 55 years. The percentage of cases positive for IHC markers of interest were 72 % for ER, 49 % for PR, 10 % for HER2, and 18 % for CK5/6 or EGFR (Supplemental Table 1 ). Patient demographic and tumor characteristics for the 227 cases selected for analysis were generally similar to the remaining cases in this population, except that tumors were larger (53 % of profiled C2.1 cm vs. 42 % not profiled; P = 0.002), more frequently ER-positive (72 % profiled vs. 65 % not profiled; P = 0.02), and more often node positive (profiled 45 vs. 36 % non-profiled P = 0.008, Supplemental Table 1 ). Additional analysis restricted to the 208 with mRNA expression data showed similar results to use of the full set of 226 samples with methylation profiling data. 93 % of the methylation markers found by the 208 samples were also found by the 226 samples; however, to increase the power of methylation markers, we selected relevant markers from the full set of 226 samples. The MEI signature we developed based on these 57 genes was defined as the sum of the mRNA expression values of the 57 genes weighted by the Spearman correlation coefficient, which we refer to as the MEI (see ''Methods'' section). Of the 57 genes, 54 showed a negative correlation between DNA methylation and mRNA expression (Table 2, Supplemental Table 2 ). The 57 genes identified through the selection process are related to a broad range of molecular functions based on gene ontology (GO), including binding, catalytic activity, enzyme and receptor activities, and other processes.
MEI score association with death among ER-positive breast cancer cases in the PBCS MEI scores approximated a normal distribution (median value = 168.172). We classified tumors as high/low MEI using the median value as the cutpoint, to evaluate its association with tumor characteristics and prognosis. Low MEI was associated with tumors that were poorly differentiated, ER-negative, PR-negative, and HER2-postive (P = \0.001), Supplemental Table 4 .
Survival analysis based on the classification of the MEI as high/low showed a significant association with survival overall; however, analysis stratified by ER status demonstrated that a significant association was restricted to ERpositive tumors. Among ER-positive breast cancer cases, low MEI was significantly associated with an increased risk of death in KM curves (P = 0.0088, Fig. 2 ) and in multivariable models adjusted for age, tumor size, node status, grade, primary hormone treatment, and secondary radiation treatment (HR = 2.85 95 % CI = 1.25-6.47, Table 3 ).
Validation of the MEI score and survival among ERpositive breast cancer cases
We generated a high/low categorical variable of MEI based on the median value of the MEI in each of four published mRNA expression datasets and evaluated its relationship with clinical outcomes. Among ER-positive breast cancer cases, low MEI was significantly associated with an increased risk of death (TCGA dataset P = 0.003, BT2000 dataset P = 1.4 9 10 -5
, NKI dataset P = 0.01) and increased risk of distant metastases (GSE6532 dataset P = 0.0019) (Fig. 3) . Tests for interaction of the MEI and ER by dataset showed significant interaction only in TCGA (P = 0.02) and not in the other datasets (PBCS, P = 0.37; NKI, P = 0.52; BT2000, P = 0.06; GSE6532, P = 0.81). Evaluation of an unweighted MEI showed similar results to the weighted MEI in the datasets PBCS, TCGA, and GSE6532; however, weighting of the markers gave more consistent findings (See Supplemental Fig. 1 ),
Discussion
In this report, we describe the development of the MEI; a prognostic signature consisting of a weighted combinatorial score of mRNA levels corresponding to 57 genes. These genes were selected because they showed significant relationships between DNA methylation levels and expression of key protein markers in the Polish Breast Cancer Study. In this study, women with ER-positive cancers and low MEI demonstrated reduced survival, and similar results were found in four large independent datasets. These results provide further support for integrated multi-platform molecular analyses to characterize tumor biology and search for prognostic signatures for breast cancer.
Although the MEI is novel, our findings are consistent with other published data. We found that the frequency of DNA methylation was higher in ER-positive as compared with ER-negative breast cancers, similar to prior studies [7, 9, 11, 30] . Two MEI genes are included in other wellknown prognostic gene expression signatures, including MLPH in the PAM50 panel and SCUBE2 in the Oncotype DX [2, 31] . DNA methylation has also been identified in histologically normal tissues surrounding breast cancers, potentially implicating methylation as an early mechanism in carcinogenesis [32] . Accordingly, identifying panels of frequently methylated genes in breast cancers and surrounding tissues related to critical changes in mRNA and protein expression may provide markers of early detection and molecular targets for prevention or treatment. Analysis not using the weights showed similar results to the weighted sum of the MEI, showing the signature to be robust and support these genes to potentially have some important biological function. Our analysis independently identified 55 genes that are not in well-known gene expression signatures (PAM50, OncotypeDx, and MammaPrint), and thus are specific to the MEI. These genes might provide further clues into the biology of aggressive ER-positive breast cancers. Some of the MEI-specific genes are well-known cancer associatedgenes, including CCND1, MUC1, MMP7, C10orf116, and KYNU-which are involved in DNA repair, cell proliferation, and cancer metastasis-and have been noted to be related to aggressive breast cancers [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] .
Strengths of our study include (1) analysis of samples from a population-based case-control study, with detailed epidemiologic data and long-term follow-up and treatment data from medical records for these cases; (2) use of high density profiling arrays; (3) availability of detailed pathology and IHC data; and (4) validation of our findings in four independent datasets. Our study was limited by small numbers of less common subtypes, including ERnegative breast cancers. Although, some differences were Fig. 3 Kaplan-Meir curves and low and high MEI among ERpositive breast cancers and association with overall or disease metastasis free survival in four independent datasets. Note: The GSE6352 dataset was missing expression data for five genes that comprised the MEI (AGR3, GLIPR2, GP1BB, S100A7, and ZG16B), while the NKI dataset was missing data from ten of the 57 genes that comprise the MEI (expression data was not available for AGR3, C1orf64, GLIPR2, GP1BB, IFITM3, MLPH, MMP7, S100A7, SCGB3A1, and ZG16B). The BT2000 dataset genes had missing expression data on GP1BB, GZMA, IL20, and CFB. All 57 genes were represented in the TCGA dataset. MEI was calculated in the four publically available datasets using gene expression data and weighted using Spearman correlation Rho values from the Polish breast cancer study (Table 2) found between the pathologic characteristics of Polish cases included in the analysis and the entire case group, confirmation of the prognostic significance of the MEI in independent datasets reduces concerns about generalizability. In addition, data were lacking from some MEI markers in the validation sets, but findings replicated nonetheless, suggesting that the signature is robust.
In conclusion, our analysis demonstrated that an integrated biomarker discovery approach in which DNA methylation profiling is integrated with mRNA expression and IHC is promising for discovering prognostic signatures for breast cancer. Specifically, discovery approaches that identify genes which show important associations at the DNA, RNA, and protein levels may improve the specificity of signatures and limit the identification of chance findings. Future prospective studies are needed to assess the performance of the MEI along with other signatures to determine how best to employ these tools to direct patient care.
